TRUEchemie Alpha Amylase Test Kit (CNPG3)

for the quantitative determination of Amylase concentration in serum or plasma

IVD

Page 1 of 1

INTENDED USE
Amylase Test Kit (CNPG3) is used for the quantitative determina-
ration in human serum or plasma.
•

The TRUEchemie Alpha

tion of Amylase concentr

PRINCIPLE

 α - Amylase is secreted from the salivary glands and exocrine pancreas. α - Amylase catalyses the hydrolysis of α -1-4-glucosidic linkages of starch and other related polysaccharides to produce maltose and other oligosaccharides. The enzyme is relatively a small molecule, which is rapidly cleared by the kidney and excreted in the urine. α -Amylase is most frequently measured in the diagnosis of acute pancreatitis when serum levels may be grossly elevated and therefore is a useful diagnostic tool in critical care management. In acute pancreatitis α - Amylase levels reach a peak at 24 hours and remain elevated from 3-7 days. Hyperamylasemia is also associated with other acute abdominal disorders. Biliary tract diseases, diabetic ketoacidosis, severe glomerular dysfunction, salivary gland disorders, and ruptured ectopic pregnancy.

INTRODUCTION

The direct amylase assay involves the use of a chromogenic substrate CNPG3 (2-chloro-4nitrophenyl linked with Galactomaltoside) which acts upon α - Amylase to release more than 95% of 2-chloro-4-nitrophenol (CNP), and form 2-chloro-4-nitrophenyl- α -D-maltoside (CNPG2), maltotriose (G3) and Glucose (G). The rate of formation of 2-chloro-4-nitrophenol is proportional to the a - Amylase activity in the sample, which can be monitored by kinetic assay at 405 nm.

α- Amylase

10	CNPG3	9CNP + CNP	PG2 + 9G3 +G
	PAG	CK SIZE	
Kit Size	-	2 x 10 ml]
Cat. No.		ADX261	
Kit contents			
 Alpha Amylase R 	eagent	2 x 10 ml	J
	REAGENT	COMPOSITION	
α- Amylase Reagent MES pH 6.50 Sodium Chloride Magnesium Chloride Calcium Chloride CNPG3 Preservatives	: 52 mmol/l : 87 mmol/l : 12.6 mmol/l : 0.075 mmol/l : 22 mmol/l		
110001100100	REAGENT P	REPARATION	
Ready to use reagents.	REAGENT		
	WARNINGS AND	PRECAUTIONS	
contact. 3. Specimens should be	e with good laborato considered infectious sodium hydroxide th seek medical attentio	s and handled appr nat is corrosive. In c	case of contact with skin, flush
	REAGENT STO	RAGE & STABIL	ITY
The unopened reagents at 2-8°C. Do not use rea			e bottle and kit label when stored
5	SPECIMEN COLLE	CTION AND STO	RAGE
Unhemolysed serum or p EDTA, Oxalate or Citrate Amylase in serum is repo 2 months when stored re	inhibit amylase activ orted to be stable for	vity hence cannot be	
M	ATERIALS REQUIR	ED BUT NOT PRO	OVIDED
1. Pipettes to accurately 2. Test tubes/rack 3. Timer			

4. 37 °C heating block or water bath

5. Photometer capable of accurately measuring absorbance at 405 nm

TEST PROCEDURE

Primary wavelength	405 nm	
Temperature	37 °C	
Prewarm the reagent to reaction temperature.		

	Blank (µL)	Sample (µL)
Distilled water	1000	
Alpha Amylase Reagent		1000
Sample		25

Blank the Photometer with D I Water

Mix, read the absorbance after 30 Sec. and start the stopwatch. Read again the absorbance after every 30 Sec upto 90 Sec

Calculations: ΔE = Initial absorbance - absorbance after every 30 Sec upto 90 Sec (Avg ∆E/min) x 4640 = Amylase U/L

QUALITY CONTROL

Quality Controls are recommended to monitor the performance of automated assay procedures Each laboratory should establish its own Quality Control scheme and corrective actions if controls do not meet the acceptable tolerances

EXPECTED VALUE

Normal values Serum, plasma: 25 - 140 U/L

It is strongly recommended that each laboratory establish its own normal range.

PERFORMANCE CHARACTERISTICS

Sensitivity: 10 U/L

Linearity: 2000 U/L under the described assay conditions. If the amylase activity is above 2000 U/L dilute the specimen suitably with normal saline. In such case the results obtained should be multiplied by dilution factor to obtain correct amylase activity. The linearity limit depends on the sample / reagent ratio, as well as the analyzers used.

Intra-assay precision within run (n=10)	Mean (U/L)	SD (U/L)	CV (%)
Control Level - 1	74.5	0.3	0.5
Control Level - 2	505.4	0.7	0.1

Inter-assay precision run to ru (n=12)	in Mean (U/L)	SD (U/L)	CV (%)
Control Level - 1	72.6	0.4	0.6
Control Level - 2	509.7	1.2	0.2

The reagent was tested for 12 days, using two different Alpha Amylase concentrations. The coefficient of variation was <5%

AUTOMATED PROCEDURE

Appropriate program sheet is available for different analyzers upon request.

METHOD COMPARISON

Results obtained using TRUEchemie Alpha Amylase reagent (y) did not show systematic differences when compared with another commercial reagent (x) with similar characteristics. The results obtained is below: The correlation coefficient (r^2) was 0.99 and the regression equation is y=0.993x+0.594. The results of the performance characteristics depend on the analyzer used.

	INTERFERENCES
Bilirubin (mixed isomers)	: Less than 10% interference up to 600 μmol.
Haemolysis	: Less than 10% interference up to 5 g
Lipemia	: Less than 10% interference up to 5 g

WASTE MANAGEMENT Please refer to local regulation requirements

	5	SYSTEM PARAMETERS
Node	:	Kinetic .
actor	:	4640
Vave length	:	405 nm
Jnits	:	U/L
low cell Temp.	:	37°C
Blank	:	Distilled Water
Reagent volume	:	1000 µL
Sample volume	:	25 μL
.ag time	:	30 Sec.
Read time	:	90 Sec.
ow Normal	:	25
High Normal	:	140
Sensitivity	:	10
_inearity	:	2000
Reaction Slope	:	Increasing

Greiling H, Gressner AM, eds. Lehrbuch des Klinischen Chemie und Pathobiochemie, 3rd ed. Stuttgart/New York: Schattauer Verlag, 1995. Burtis CA., Ashwood ER. Tietz Fund. Of Clin. Chem. 5th ed.; 30-54, 372-378 and 964. 1.

2 Tietz NW, ed. Clinical Guide to Laboratory Tests, 3rd ed.Philadelphia, PA:WB Saunders, 1995; 46-51. 3.

4. Hohenwallner W, Hagele EO, Scholer A et al. Ber Oster Ges Klin Chem 1983; 6.101-112

5 Junge W, Waldenstrom J, Bouman A et al. Evaluation of the Assays for Total and Pancreatic O-Amylase based on 100% Cleavage of ET-G7-PNP at 6 European Clinical Centres (Poster Mediab 97). Basel, Switzerland; 12 th IFCC European Congress of Clinical Chemistry, August 17-22, 1997. ISO 15223-1:2021 Medical devices — Symbols to be used with information to be

6. supplied by the manufacturer - Part 1: General requirements

Index of Symbols

